Published in J Infect Dis on July 01, 1997
Human parvovirus B19. Clin Microbiol Rev (2002) 3.44
New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections. J Clin Microbiol (2001) 0.93
Human Parvoviruses. Clin Microbiol Rev (2017) 0.84
Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients. Mem Inst Oswaldo Cruz (2014) 0.81
Nondiagnostic bone marrow in parvovirus B19-related anemia in AIDS: confounding effect of prior transfusion? J Infect Dis (1998) 0.75
Influenza A and Parvovirus B19 Seropositivity Rates in Gabonese Infants. Am J Trop Med Hyg (2015) 0.75
Acute human parvovirus b19 infection: cytologic diagnosis. Indian J Hematol Blood Transfus (2013) 0.75
Prevalence of HIV-related autoimmune haemolytic anaemia in Lagos, Nigeria. Niger Med J (2014) 0.75
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med (1994) 4.86
CliniWeb: managing clinical information on the World Wide Web. J Am Med Inform Assoc (1996) 4.13
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood (1990) 3.65
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med (1987) 2.93
Nonequivalent nuclear location of immunoglobulin alleles in B lymphocytes. Nat Immunol (2001) 2.83
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. J Clin Invest (1972) 2.61
Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev (2000) 2.55
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev (1998) 2.37
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A (1985) 2.33
Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 2.26
Detection of influenza A(H3N2) virus in children with suspected mumps during winter 2014/15 in England. Euro Surveill (2015) 2.19
Attitudes toward assisted suicide and euthanasia among physicians in Washington State. N Engl J Med (1994) 2.18
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med (1999) 2.17
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet (1988) 1.97
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology (1996) 1.97
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood (1995) 1.91
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Affinity modulation of integrin alpha 5 beta 1: regulation of the functional response by soluble fibronectin. J Cell Biol (1993) 1.86
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med (1989) 1.85
Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A (1992) 1.82
Prediction of pneumonia in outpatients with acute cough--a statistical approach. J Chronic Dis (1984) 1.80
Characterization of a virus that causes transient aplastic crisis. J Clin Invest (1984) 1.78
Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA (1984) 1.77
Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood (1992) 1.76
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol (1993) 1.76
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood (1994) 1.75
Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia: evidence of interspecies communication. J Bacteriol (1995) 1.74
Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol (2000) 1.73
Poverty and HIV seropositivity: the poor are more likely to be infected. AIDS (1990) 1.72
Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood (1989) 1.69
The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro Surveill (2012) 1.67
Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med (1984) 1.66
Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med (1995) 1.65
Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest (1992) 1.63
Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol (1989) 1.56
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood (1996) 1.56
Correction of the PNH defect by GPI-anchored protein transfer. Blood (1998) 1.55
Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Blood (1997) 1.55
Inhibitory action of fatty acids on the growth of Neisseria gonorrhoeae. Infect Immun (1977) 1.53
MAP kinase activation by flow in endothelial cells. Role of beta 1 integrins and tyrosine kinases. Circ Res (1996) 1.52
Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol (1991) 1.50
A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J Virol (1992) 1.48
A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem (1995) 1.47
Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. J Thromb Haemost (2012) 1.47
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 1.47
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med (1994) 1.45
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol (1993) 1.45
Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med (1985) 1.43
Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood (1986) 1.42
Fanconi anemia and novel strategies for therapy. Blood (1994) 1.39
Stimulation of integrin-mediated adhesion of T lymphocytes and monocytes: two mechanisms with divergent biological consequences. J Exp Med (1994) 1.39
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest (1994) 1.39
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol (1984) 1.38
Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology (1997) 1.38
Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol (1995) 1.33
Fabrication of an ocular prosthesis. J Prosthet Dent (1970) 1.32
Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood (1996) 1.32
A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol (1994) 1.30
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A (1996) 1.29
Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol (1994) 1.28
The interaction of heparin sulfate and adeno-associated virus 2. Virology (2000) 1.28
Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A (1994) 1.28
Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther (1999) 1.28
Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol (1995) 1.27
gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med (1994) 1.26
Identification of a novel simian parvovirus in cynomolgus monkeys with severe anemia. A paradigm of human B19 parvovirus infection. J Clin Invest (1994) 1.26
Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood (2000) 1.25
Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) (1992) 1.25
A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. Virology (1999) 1.25
Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J Cell Biol (1992) 1.25
Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest (2001) 1.25
A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood (1996) 1.24
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood (2001) 1.24
Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol (1985) 1.23
Clinical considerations improving obturator treatment. J Prosthet Dent (1970) 1.23